Cargando…

Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial

To compare the efficacy and safety of induction chemotherapy (IC) followed by intensity‐modulated radiotherapy (IMRT) alone versus concurrent CCRT in locoregionally advanced nasopharyngeal carcinoma (LA‐NPC). Patients with newly diagnosed stage III to IVB nasopharyngeal carcinoma (NPC) were randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhining, Cai, Zeman, Cai, Qingxin, Hong, Yingji, Zhang, Cuidai, Huang, Kaichun, Lin, Zhixiong, Li, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209609/
https://www.ncbi.nlm.nih.gov/pubmed/33955190
http://dx.doi.org/10.1002/cam4.3936
_version_ 1783709163131502592
author Yang, Zhining
Cai, Zeman
Cai, Qingxin
Hong, Yingji
Zhang, Cuidai
Huang, Kaichun
Lin, Zhixiong
Li, Mei
author_facet Yang, Zhining
Cai, Zeman
Cai, Qingxin
Hong, Yingji
Zhang, Cuidai
Huang, Kaichun
Lin, Zhixiong
Li, Mei
author_sort Yang, Zhining
collection PubMed
description To compare the efficacy and safety of induction chemotherapy (IC) followed by intensity‐modulated radiotherapy (IMRT) alone versus concurrent CCRT in locoregionally advanced nasopharyngeal carcinoma (LA‐NPC). Patients with newly diagnosed stage III to IVB nasopharyngeal carcinoma (NPC) were randomized to receive IC plus IMRT (IC+RT arm), or concurrent chemotherapy plus IMRT (CCRT arm), using a random number table. Both treatment arms received the same chemotherapy regimen. The primary endpoint was progression‐free survival (PFS). Secondary end points included overall survival (OS), locoregional recurrence‐free survival (LRRFS), distant metastasis‐free survival (DMFS), treatment response, and acute treatment toxicities. From June 2013 to September 2018, a total of 204 patients histologically diagnosed with LA‐NPC were enrolled in the study, with 102 patients randomly assigned to each arm. After a median follow‐up duration of 45 months (range 4 to 84 months), the 3‐year PFS, OS, LRRFS and DMFS were 72.2%, 87.8%, 92.3%, and 82.7% in the IC+RT arm, compared with 82.6%, 92.8%, 94.7%, and 88.2% in the CCRT arm. No statistical difference for PFS, OS, LRRFS, DMFS, or treatment response was observed between the two arms (p > 0.05). The incidences of leukopenia (p = 0.008) and anemia (p = 0.015) were significantly higher in patients in the CCRT arm than those in the IC+RT arm. Compared to CCRT, IC plus IMRT alone provided similarly favorable treatment outcomes in terms of PFS, OS, LRRFS, and DMFS for patients with LA‐NPC, but resulted in fewer incidences of leukopenia and anemia.
format Online
Article
Text
id pubmed-8209609
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82096092021-06-25 Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial Yang, Zhining Cai, Zeman Cai, Qingxin Hong, Yingji Zhang, Cuidai Huang, Kaichun Lin, Zhixiong Li, Mei Cancer Med Clinical Cancer Research To compare the efficacy and safety of induction chemotherapy (IC) followed by intensity‐modulated radiotherapy (IMRT) alone versus concurrent CCRT in locoregionally advanced nasopharyngeal carcinoma (LA‐NPC). Patients with newly diagnosed stage III to IVB nasopharyngeal carcinoma (NPC) were randomized to receive IC plus IMRT (IC+RT arm), or concurrent chemotherapy plus IMRT (CCRT arm), using a random number table. Both treatment arms received the same chemotherapy regimen. The primary endpoint was progression‐free survival (PFS). Secondary end points included overall survival (OS), locoregional recurrence‐free survival (LRRFS), distant metastasis‐free survival (DMFS), treatment response, and acute treatment toxicities. From June 2013 to September 2018, a total of 204 patients histologically diagnosed with LA‐NPC were enrolled in the study, with 102 patients randomly assigned to each arm. After a median follow‐up duration of 45 months (range 4 to 84 months), the 3‐year PFS, OS, LRRFS and DMFS were 72.2%, 87.8%, 92.3%, and 82.7% in the IC+RT arm, compared with 82.6%, 92.8%, 94.7%, and 88.2% in the CCRT arm. No statistical difference for PFS, OS, LRRFS, DMFS, or treatment response was observed between the two arms (p > 0.05). The incidences of leukopenia (p = 0.008) and anemia (p = 0.015) were significantly higher in patients in the CCRT arm than those in the IC+RT arm. Compared to CCRT, IC plus IMRT alone provided similarly favorable treatment outcomes in terms of PFS, OS, LRRFS, and DMFS for patients with LA‐NPC, but resulted in fewer incidences of leukopenia and anemia. John Wiley and Sons Inc. 2021-05-06 /pmc/articles/PMC8209609/ /pubmed/33955190 http://dx.doi.org/10.1002/cam4.3936 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Yang, Zhining
Cai, Zeman
Cai, Qingxin
Hong, Yingji
Zhang, Cuidai
Huang, Kaichun
Lin, Zhixiong
Li, Mei
Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial
title Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial
title_full Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial
title_fullStr Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial
title_full_unstemmed Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial
title_short Sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase II, single center, randomized, non‐inferiority trial
title_sort sequential induction chemotherapy plus intensity‐modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three‐year report of a phase ii, single center, randomized, non‐inferiority trial
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209609/
https://www.ncbi.nlm.nih.gov/pubmed/33955190
http://dx.doi.org/10.1002/cam4.3936
work_keys_str_mv AT yangzhining sequentialinductionchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomathethreeyearreportofaphaseiisinglecenterrandomizednoninferioritytrial
AT caizeman sequentialinductionchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomathethreeyearreportofaphaseiisinglecenterrandomizednoninferioritytrial
AT caiqingxin sequentialinductionchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomathethreeyearreportofaphaseiisinglecenterrandomizednoninferioritytrial
AT hongyingji sequentialinductionchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomathethreeyearreportofaphaseiisinglecenterrandomizednoninferioritytrial
AT zhangcuidai sequentialinductionchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomathethreeyearreportofaphaseiisinglecenterrandomizednoninferioritytrial
AT huangkaichun sequentialinductionchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomathethreeyearreportofaphaseiisinglecenterrandomizednoninferioritytrial
AT linzhixiong sequentialinductionchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomathethreeyearreportofaphaseiisinglecenterrandomizednoninferioritytrial
AT limei sequentialinductionchemotherapyplusintensitymodulatedradiotherapyversusconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomathethreeyearreportofaphaseiisinglecenterrandomizednoninferioritytrial